M Pharma Transparency Home > About Us > Transparency The Mitsubishi Tanabe Pharma Group engages Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) across Europe. We are committed to ensuring transparency in our interaction with HCPs and HCOs. In accordance with the EFPIA Code of Transfers of Value from Pharmaceutical Companies 2014, details of Transfers of Value made to HCPs and HCOs in Europe by the Mitsubishi Tanabe Pharma Group can be found below. The Methodology applied in preparing and collating these figures is available here in English*, French* and German*. If you are a Healthcare Professional and have any questions regarding the figures disclosed, please contact: Finance@mt-pharma-eu.com. 2020 Transfers of Value Austria Research & Development EUR 27,567.52 Non-Research & Development EUR 39,013.10 Full details here Belgium Research & Development EUR 41,677.50 Non-Research & Development EUR 7,500.00 Full details here Bulgaria Research & Development EUR 0.00 Non-Research & Development EUR 0.00 Full details here Croatia Research & Development EUR 0.00 Non-Research & Development EUR 0.00 Full details here Cyprus Research & Development EUR 0.00 Non-Research & Development EUR 0.00 Full details here Czech Republic Research & Development EUR 4,536.23 Non-Research & Development EUR 0.00 Full details here Denmark Research & Development EUR 0.00 Non-Research & Development EUR 0.00 Full details here Estonia Research & Development EUR 0.00 Non-Research & Development EUR 0.00 Full details here Finland Research & Development EUR 0.00 Non-Research & Development EUR 0.00 Full details here France Research & Development EUR 441,861.75 Non-Research & Development EUR 5,000.00 Full details here Germany Research & Development EUR 39,402.76 Non-Research & Development EUR 81,295.45 Full details here Greece Research & Development EUR 0.00 Non-Research & Development EUR 0.00 Full details here Hungary Research & Development HUF 430,000.00 Non-Research & Development HUF 0.00 Full details here Ireland Research & Development EUR 193,699.64 Non-Research & Development EUR 0.00 Full details here Italy Research & Development EUR 89,773.40 Non-Research & Development EUR 0.00 Full details here Latvia Research & Development EUR 0.00 Non-Research & Development EUR 0.00 Full details here Lithuania Research & Development EUR 0.00 Non-Research & Development EUR 0.00 Full details here Malta Research & Development EUR 0.00 Non-Research & Development EUR 0.00 Full details here The Netherlands Research & Development EUR 173,296.00 Non-Research & Development EUR 0.00 Full details here Norway Research & Development EUR 0.00 Non-Research & Development EUR 0.00 Full details here Poland Research & Development EUR 50,792.89 Non-Research & Development EUR 0.00 Full details here Portugal Research & Development EUR 0.00 Non-Research & Development EUR 0.00 Full details here Romania Research & Development EUR 0.00 Non-Research & Development EUR 0.00 Full details here Russia Research & Development EUR 5,716.46 Non-Research & Development EUR 0.00 Full details here Serbia Research & Development RSD 1,643,600.00 Non-Research & Development RSD 0.00 Full details here Slovakia Research & Development EUR 3,877.50 Non-Research & Development EUR 0.00 Full details here Slovenia Research & Development EUR 0.00 Non-Research & Development EUR 0.00 Full details here Spain Research & Development EUR 17,238.30 Non-Research & Development EUR 0.00 Full details here Sweden Research & Development SEK 180,900.00 Non-Research & Development SEK 0.00 Full details here Switzerland Research & Development CHF 56,243.20 Non-Research & Development CHF 50,592.82 Full details here Turkey Research & Development EUR 0.00 Non-Research & Development EUR 0.00 Full details here Ukraine Research & Development UAH 17,250.00 Non-Research & Development UAH 0.00 Full details here United Kingdom Research & Development GBP 24,302.95 Non-Research & Development GBP 36,266.67 Full details here or here (ABPI Website) * The Mitsubishi Tanabe Pharma Group has established legal entities in the United Kingdom, Germany and Switzerland and therefore disclosure is made according to local requirements for these countries In this section CORPORATE OVERVIEW & POLICIES PHILOSOPHY & VISION TRANSPARENCY 2018 TRANSFERS OF VALUE 2019 TRANSFERS OF VALUE Sitemap ABOUT US CLINICAL RESEARCH DISEASE AREAS WORK FOR US MEDIA CONTACT US Terms and Privacy TERMS OF USE PRIVACY POLICY COOKIE POLICY Contact Us MITSUBISHI TANABE PHARMA EUROPE LTD DASHWOOD HOUSE 69 OLD BROAD STREET LONDON EC2M 1QS UNITED KINGDOM +44 (0) 207 065 5000 FULL CONTACT DETAILS © 2021 Mitsubishi Tanabe Pharma Europe Ltd Website by Fat Media